← Leaderboards
Nicholas M Kanaan
Michigan State University
$11,893,156
Attributed
$16,201,827
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2014–25$2.5M$1.9M$1.3M$625K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,201,827 · 8
By mechanism
R01$11,525,543 · 3
P30$1,793,680 · 1
RF1$1,592,854 · 1
R21$1,289,750 · 3
Top collaborators
- Scott Thomas Brady11 shared
Most similar at Michigan State University
Same institution · by research overlap
- Scott Edward Counts$9,145,000
- Rebecca Lynn Mueller$58,606
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposS DiseaseTau ProteinsTau MutationAffectLinkTauopathiesSynapsesPathologyAxonal TransportNeuronsPhosphoric Monoester HydrolasesAxonMolecularTau FunctionProtein PhosphataseS Disease Related DementiaProteinsAntibodiesModificationTau AggregationPhysiologicalBrainSignal Transduction
Grant awards (29)
Tau Conformation in Tauopathies and Neuronal Function$1,592,854
RF1 · FY2025 · NS
Core F: Biomarker Core$448,964
P30 · FY2025 · AG · contact PI
Tau-Mediated Regulation and Dysregulation of Protein Phosphatase 1$527,028
R01 · FY2024 · AG · contact PI
Tau Oligomeric Complex 1 Antibody as a Novel Immuno-Gene Therapy for Tauopathy.$431,750
R21 · FY2024 · AG · contact PI
Development and Validation of a Novel Anti-Pathogenic Tau Conformation (TNT2) scFv Immuno-Gene Therapy$431,750
R21 · FY2024 · AG · contact PI
Core F: Biomarker Core$280,215
P30 · FY2024 · AG · contact PI
Tau Conformation in Tauopathies and Neuronal Function$772,520
R01 · FY2023 · NS
Tau-Mediated Regulation and Dysregulation of Protein Phosphatase 1$527,028
R01 · FY2023 · AG · contact PI
Core F: Biomarker Core$338,120
P30 · FY2023 · AG · contact PI
Tau Conformation in Tauopathies and Neuronal Function$775,807
R01 · FY2022 · NS
Tau-Mediated Regulation and Dysregulation of Protein Phosphatase 1$527,028
R01 · FY2022 · AG · contact PI
Core F: Biomarker Core$353,770
P30 · FY2022 · AG · contact PI
Tau Conformation in Tauopathies and Neuronal Function$778,179
R01 · FY2021 · NS
Tau-Mediated Regulation and Dysregulation of Protein Phosphatase 1$527,028
R01 · FY2021 · AG · contact PI
Core F: Biomarker Core$372,611
P30 · FY2021 · AG · contact PI
Tau Conformation in Tauopathies and Neuronal Function$783,638
R01 · FY2020 · NS
Tau-Mediated Regulation and Dysregulation of Protein Phosphatase 1$527,028
R01 · FY2020 · AG · contact PI
Development of Novel Tau-SIMOA Assays$426,250
R21 · FY2020 · AG · contact PI
Tau Conformation in Tauopathies and Neuronal Function$800,769
R01 · FY2019 · NS
Tau Conformation in Tauopathies and Neuronal Function$619,740
R01 · FY2018 · NS
Tau-induced axonal degeneration in Alzheimer's disease and tauopathies$384,710
R01 · FY2018 · AG · contact PI
Tau Conformation in Tauopathies and Neuronal Function$619,740
R01 · FY2017 · NS
Tau-induced axonal degeneration in Alzheimer's disease and tauopathies$384,710
R01 · FY2017 · AG · contact PI
Tau Conformation in Tauopathies and Neuronal Function$619,740
R01 · FY2016 · NS
Tau-induced axonal degeneration in Alzheimer's disease and tauopathies$384,710
R01 · FY2016 · AG · contact PI
Tau Conformation in Tauopathies and Neuronal Function$619,740
R01 · FY2015 · NS
Tau-induced axonal degeneration in Alzheimer's disease and tauopathies$378,670
R01 · FY2015 · AG · contact PI
Tau Conformation in Tauopathies and Neuronal Function$634,615
R01 · FY2014 · NS
Tau-induced axonal degeneration in Alzheimer's disease and tauopathies$333,115
R01 · FY2014 · AG · contact PI